IC
PTCT icon

Ikarian Capital’s PTC Therapeutics PTCT Stock Holding History

Ikarian Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-213,000
Closed -$13.1M – 213
2025
Q3 		$13.1M Buy
+213,000
New +$11.1M 1.32% 17
2023
Q2 		– Sell
-9,800
Closed -$475K – 152
2023
Q1 		$475K Buy
+9,800
New +$448K 0.11% 97

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Ikarian Capital's PTCT Position: Q1 2026 in Review

Ikarian Capital sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 118,657 shares — an estimated $9.01M sold.

Ikarian Capital first reported a position in PTCT in Q3 2023 and held it in 3 quarters. The position peaked at $17.2M in Q3 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Ikarian Capital reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Ikarian Capital sold 118,657 PTC Therapeutics shares in Q1 2026, an estimated $9.01M.
  • Ikarian Capital first reported a position in PTC Therapeutics in Q3 2023 and held it in 3 quarters.
  • Ikarian Capital's PTC Therapeutics position peaked at $17.2M in Q3 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.